Literature DB >> 1879447

Radionuclide therapy revisited.

C A Hoefnagel1.   

Abstract

Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours. After a brief introduction of some basic principles of radionuclide targeting, the therapeutic radiopharmaceuticals available are reviewed according to the accumulation site in relation to the cell nucleus; the results of their current clinical use for therapy are also reviewed. The response observed to a number of these applications, the non-invasiveness of the procedure and the relative lack of toxicity and late effects in comparison with chemotherapy and external beam radiotherapy make radionuclide therapy an attractive and realistic alternative in the management of malignant disease, as well as in the treatment of a few benign disorders.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879447     DOI: 10.1007/bf02258432

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  155 in total

1.  The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum.

Authors:  D PRESSMAN; G KEIGHLEY
Journal:  J Immunol       Date:  1948-06       Impact factor: 5.422

2.  Therapeutic use of 90Y microspheres.

Authors:  G J Ehrhardt; D E Day
Journal:  Int J Rad Appl Instrum B       Date:  1987

3.  [Radio-isotopic synoviorthesis of finger joints in rheumatoid arthritis].

Authors:  C J Menkes; P Verrier; A Le Go; F Delbarre
Journal:  Ann Chir       Date:  1974-11

4.  [Synoviorthesis with 90yttrium (author's transl)].

Authors:  W Müller; R Fridrich; K Pavelka
Journal:  Dtsch Med Wochenschr       Date:  1974-05-10       Impact factor: 0.628

Review 5.  Radiobiologic implications of the microscopic distribution of energy from radionuclides.

Authors:  S J Adelstein; A I Kassis
Journal:  Int J Rad Appl Instrum B       Date:  1987

6.  Thyroid remnant ablation: questionable pursuit of an ill-defined goal.

Authors:  J Snyder; C Gorman; P Scanlon
Journal:  J Nucl Med       Date:  1983-08       Impact factor: 10.057

Review 7.  Radionuclide diagnosis and therapy of thyroid cancer: current status report.

Authors:  J E Freitas; M D Gross; S Ripley; B Shapiro
Journal:  Semin Nucl Med       Date:  1985-04       Impact factor: 4.446

8.  Iodine-131 therapy for parotid oncocytoma.

Authors:  S Kosuda; M Ishikawa; K Tamura; M Mukai; A Kubo; S Hashimoto
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

9.  Radionuclide therapy of neural crest tumors.

Authors:  P A Voûte; C A Hoefnagel; J de Kraker; A E Evans; A Hayes; A Green
Journal:  Med Pediatr Oncol       Date:  1987

10.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more
  18 in total

1.  Nuclear medicine 2013: from status quo to status go.

Authors:  Thomas Beyer; Marcus Hacker; August Schubiger; Irene Virgolini; Hans-Jürgen Wester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-03       Impact factor: 9.236

Review 2.  New peptide and protein drugs.

Authors:  P Vermeij; D Blok
Journal:  Pharm World Sci       Date:  1996-06

Review 3.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

Review 4.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

5.  153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms.

Authors:  Fernanda Marques; Krassimira P Guerra; Lurdes Gano; Judite Costa; M Paula Campello; Luís M P Lima; Rita Delgado; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2004-08-28       Impact factor: 3.358

Review 6.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

Review 7.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

Review 8.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

9.  Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.

Authors:  M Nocaudie-Calzada; D Huglo; B Carnaille; C Proye; X Marchandise
Journal:  Eur J Nucl Med       Date:  1996-11

10.  Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan.

Authors:  A Castagnoli; G Biti; M T De Cristofaro; P Ferri; S M Magrini; M G Papi; S Bianchi
Journal:  Eur J Nucl Med       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.